Head to head
Evolus vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: EOLS · TAK
EOLS
Evolus
7.59-1.94%
1-year price shape — +24% over the period
Quant Rating B · 75/100
vs
TAK
Takeda Pharmaceutical
18.29-0.44%
1-year price shape — +29% over the period
Quant Rating C · 70/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has done best over the past year (+29%); Takeda Pharmaceutical pays the highest dividend yield; Takeda Pharmaceutical earns the most per share.
| EOLS | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 7.59 | 18.29 |
| Change today | -1.94% | -0.44% |
| 1-year return | +23.6% | +29.2% |
| Market cap | $501.32M | $58.43B |
| 52-week range | 3.86 – 9.31 | 12.77 – 19.10 |
| Valuation | ||
| P/E (TTM) | -14.32 | -55.42 |
| P/E percentile, own 5-yr range | 12th | 4th |
| P/B | -16.22 | 1.22 |
| Dividend yield | 0.00% | 3.27% |
| Profitability & growth | ||
| EPS (TTM) | -0.80 | -0.31 |
| Net profit (TTM) | $-52.84M | $-977.54M |
| Revenue (TTM) | $316.49M | $4.62T |
| Revenue growth (YoY) | +21.2% | +10.2% |
| Gross margin | 66.7% | 65.5% |
| Operating margin | -6.5% | 10.4% |
| Net margin | -10.8% | -3.5% |
| Free cash flow (TTM) | $-21.90M | $626.68B |
| Ownership & sentiment | ||
| Institutional ownership | 77.3% | 51.5% |
| Insider activity (12mo) | 28 buy / 22 sell | 22 buy / 28 sell |
| Short interest (% of float) | 8.4% | 0.1% |
| Analyst consensus | 80% buy / 20% hold (5) | 100% buy (1) |
| Analyst price target | $14 (+89%) | $43 (+135%) |
| StockVane view | ||
| StockVane Quant Rating | B (75) | C (70) |
| Company | ||
| Employees | 334 | 47,029 |
| Founded | 2012 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.